EUVIMEDEUVIMED entdecken
Crossref

The efficacy and safety of lenvatinib plus pembrolizumab in vulnerable patients with metastatic or recurrent endometrial cancer: a single institution experience

Mayu Yunokawa, Akiko Abe, Xiaofei Wang, Yusuke Toyohara, Ryo Nimura, Takayuki Komoto, Satoki Misaka, Teruyuki Yoshimitsu, Ai Ikki, Mayumi Kamata, Shogo Nishino, Motoko Kanno und 8 weitere

International Journal of Clinical Oncology · 2025

DOI: 10.1007/s10147-024-02667-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Clinical Oncology, 2025. Verfasst von Mayu Yunokawa und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, The Cancer Institute Hospital of Japanese Foundation of Cancer Research, 3-8-31 Ariake, KoutouKuu, Tokyo, 135-8550, Japan. …. Hauptthemen laut MEDLINE: Phenylurea Compounds, Antibodies, Monoclonal, Humanized, Endometrial Neoplasms, Quinolines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Effective management with second-line therapy with the lenvatinib + pembrolizumab regimen for patients with advanced endometrial cancer is necessary. METHODS: This retrospective study enrolled patients with endometrial cancer treated with the lenvatinib + pembrolizumab regimen. We evaluated progression-free survival (PFS), overall survival (OS), safety for patients non-eligible for the KEYNOTE775 trial, aged ≥65 years, or with ECOG performance status 1-2. RESULTS: Forty-five patients were analyzed: 21 (47%) were aged ˃ 65 years, 16 (36%) had performance status 1-2, and 15 (33%) were non-eligible for KEYNOTE775 trial participation. Overall, the median PFS was 8.5 months (95% confidence interval [CI] 4.6-12.4), and the median OS was 15.6 months (95% CI 9.4-NA). Median PFS was significantly shorter in patients not eligible for KEYNOTE775 participation and with performance status 1-2. The median OS was significantly shorter in patients with performance status 1-2. Grade ˃3 adverse events (AEs) occurred in 78% of patients who received the lenvatinib + pembrolizumab regimen. AEs resulted in lenvatinib dose reductions in 35 patients (78%) and lenvatinib and pembrolizumab discontinuation in 3 (7%) and 5 (11%), respectively. The median time to the first lenvatinib dose reduction was 1.5 (0.92-2.3) months in all patients and was significantly shorter in patients aged >65 years. CONCLUSIONS: The current regimen has favorable efficacy and manageable safety with appropriate dose reduction of lenvatinib in the real world. However, the efficacy may be inferior in patients with performance status 1 or 2, heavily treated patients, and those with organ dysfunction. The current treatment status should reflect real-world data relative to the medical environment and management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phenylurea CompoundsAntibodies, Monoclonal, HumanizedEndometrial NeoplasmsQuinolinesAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Recurrence, LocalHumansFemaleAgedRetrospective StudiesMiddle AgedAged, 80 and overProgression-Free SurvivalAdultTreatment Outcome

Stichwörter der Autor:innen

KEYNOTE775LenvatinibMetastatic endometrial cancerPembrolizumabReal-worldRecurrent endometrial cancer

Substanzen

lenvatinibPhenylurea CompoundspembrolizumabAntibodies, Monoclonal, HumanizedQuinolines

Autor:innen und Institutionen

  • Department of Gynecology, The Cancer Institute Hospital of Japanese Foundation of Cancer Research, 3-8-31 Ariake, KoutouKuu, Tokyo, 135-8550, Japan. mayu.yunokawa@jfcr.or.jp.
  • Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation of Cancer Research, Tokyo, Japan. mayu.yunokawa@jfcr.or.jp.
  • Department of Gynecology, The Cancer Institute Hospital of Japanese Foundation of Cancer Research, 3-8-31 Ariake, KoutouKuu, Tokyo, 135-8550, Japan.
  • Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation of Cancer Research, Tokyo, Japan.

Zitieren

APA

Yunokawa, M., Abe, A., Wang, X., Toyohara, Y., Nimura, R., Komoto, T., Misaka, S., Yoshimitsu, T., Ikki, A., Kamata, M., Nishino, S., Kanno, M., Fusegi, A., Netsu, S., Aoki, Y., Omi, M., Tanigawa, T., Okamoto, S., Nomura, H., & Kanao, H. (2025). The efficacy and safety of lenvatinib plus pembrolizumab in vulnerable patients with metastatic or recurrent endometrial cancer: a single institution experience. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-024-02667-0

Vancouver

Yunokawa M, Abe A, Wang X, Toyohara Y, Nimura R, Komoto T, et al. The efficacy and safety of lenvatinib plus pembrolizumab in vulnerable patients with metastatic or recurrent endometrial cancer: a single institution experience. International Journal of Clinical Oncology. 2025. doi:10.1007/s10147-024-02667-0

BibTeX
@article{Yunokawa2025,
  author = {Yunokawa, Mayu and Abe, Akiko and Wang, Xiaofei and Toyohara, Yusuke and Nimura, Ryo and Komoto, Takayuki and Misaka, Satoki and Yoshimitsu, Teruyuki and Ikki, Ai and Kamata, Mayumi and Nishino, Shogo and Kanno, Motoko and Fusegi, Atsushi and Netsu, Sachiho and Aoki, Yoichi and Omi, Makiko and Tanigawa, Terumi and Okamoto, Sanshiro and Nomura, Hidetaka and Kanao, Hiroyuki},
  title = {The efficacy and safety of lenvatinib plus pembrolizumab in vulnerable patients with metastatic or recurrent endometrial cancer: a single institution experience},
  journal = {International Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1007/s10147-024-02667-0}
}
Kostenlos starten →